AI assistant
PFIZER INC — Director's Dealing 2025
Mar 3, 2025
29831_dirs_2025-03-03_bd73bd94-041b-43f6-9ec6-b22f8381b409.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2025-02-27
Reporting Person: McDermott Michael (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-27 | Common Stock | M | 48419.0000 | $31.3100 | Acquired | 122413.0000 | Direct |
| 2025-02-27 | Common Stock | F | 1108.0000 | $26.1000 | Disposed | 121305.0000 | Direct |
| 2025-02-27 | Common Stock | F | 45347.0000 | $26.0600 | Disposed | 75958.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-27 | Stock Appreciation Rights | $31.3100 | M | 48419.0000 | Disposed | 2025-02-27 | Common Stock (48419.0000) | Direct |
Footnotes
F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F4: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.